SparingVision Conference Participation in H1 2023
SparingVision Conference Participation in H1 2023 Paris, January 31, 2023 – SparingVision (“the Company”), a…
We are a clinical-stage genomic medicines company leading a step shift in how ocular diseases are treated. We are going beyond single gene correction therapies to deliver new treatments to patients affected by Inherited Retinal Diseases (IRDs), regardless of genetic cause.